Xanthine Oxidase Inhibitor — Urate-lowering Therapy
Pregnancy: Avoid — insufficient data; animal studies suggest teratogenicity. Acute gout in pregnancy: manage with colchicine or low-dose prednisolone.
Allopurinol
Brand names: Zyloric
Adult dose
Dose: Gout (urate-lowering): 100mg OD initially (start during quiescent period — NOT during acute flare); increase by 100mg every 4 weeks to target serum urate <360 micromol/L (ideally <300 micromol/L in tophaceous gout); usual maintenance 200–300mg OD; maximum 900mg daily. Tumour lysis syndrome prophylaxis: 300mg OD starting 24h before chemotherapy.
Route: Oral
Frequency: Once daily (after meals)
Max: 900mg daily
DO NOT start during acute gout flare — can prolong or worsen the acute attack by mobilising urate crystals. Start prophylactic colchicine 500 micrograms BD (or low-dose NSAID) for 3–6 months when starting allopurinol to prevent flares. Dose titrated against serum urate target (not symptoms). Continue lifelong in most patients.
Paediatric dose
Dose: 5 mg/kg
Route: Oral
Frequency: Once daily
Max: 400mg daily
BNFc: Enzyme disorder associated with hyperuricaemia (Lesch-Nyhan): 10–20mg/kg/day. Tumour lysis syndrome prophylaxis: 10mg/kg/day (max 400mg daily). Seek specialist paediatric opinion.
Dose adjustments
Renal
eGFR 10–50: start at 50mg OD; increase slowly. eGFR <10: 50–100mg every 2–3 days. Dose titrated to serum urate target regardless of eGFR — go slowly.
Hepatic
Use with caution in hepatic impairment — hepatic metabolism; monitor LFTs.
Paediatric weight-based calculator
BNFc: Enzyme disorder associated with hyperuricaemia (Lesch-Nyhan): 10–20mg/kg/day. Tumour lysis syndrome prophylaxis: 10mg/kg/day (max 400mg daily). Seek specialist paediatric opinion.
Clinical pearls
- Azathioprine interaction is potentially fatal — ALWAYS check if patient is on azathioprine (or mercaptopurine) before prescribing allopurinol. If both needed, reduce azathioprine dose by 75% and monitor FBC closely. Many hospitals have alerts for this combination
- HLA-B*5801 screening: mandatory before prescribing in Han Chinese, Thai, and Korean patients — this allele confers very high risk of SJS/TEN (up to 100-fold increased risk in renal impairment)
- Colchicine prophylaxis: start 500 micrograms BD at the same time as allopurinol — reduces initiation flares by 85%. Continue for minimum 3–6 months (or until serum urate stable for 6 months)
- Serum urate target: <360 micromol/L (6mg/dL) for most; <300 micromol/L (5mg/dL) for tophaceous gout — check urate every 4 weeks during titration
Contraindications
- Acute gout flare (do not initiate — wait until flare resolves)
- Hypersensitivity to allopurinol
- HLA-B*5801 allele (Han Chinese, Thai, Korean ancestry — high risk of SJS/TEN — screen before prescribing per MHRA/NICE)
Side effects
- Rash (common — mild; if severe rash develops, stop immediately and do not rechallenge)
- Stevens-Johnson syndrome / TEN (rare — particularly in HLA-B*5801 carriers and CKD)
- Gout flare (paradoxical — at initiation; prevented by prophylactic colchicine)
- Nausea, diarrhoea
- Hepatotoxicity (rare)
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms — rare)
Interactions
- Azathioprine / mercaptopurine — CRITICAL: allopurinol inhibits xanthine oxidase, the enzyme that metabolises azathioprine; levels rise 3–4 fold; life-threatening bone marrow suppression. Reduce azathioprine dose by 75% if combination unavoidable; normally avoid
- Ampicillin / amoxicillin — increased incidence of rash (not a contraindication but warn patient)
- Warfarin — allopurinol increases warfarin levels; monitor INR
- Ciclosporin — increases ciclosporin levels; monitor
Monitoring
- Serum urate (every 4 weeks during titration; then 6 monthly when stable — target <360 micromol/L)
- FBC and LFTs (baseline and 3 monthly in first year)
- Renal function
- Gout flare frequency
Reference: BNFc; BNF 90; NICE NG219 (Gout); BSR Gout Guidelines 2017. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- ACC/AHA Pooled Cohort Equations (ASCVD Risk) · Cardiovascular Risk
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- DAPT Decision Tool (Ticagrelor vs Clopidogrel) · Antiplatelet Therapy
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
Drugs
Pathways
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023